GDPoster

Mark Kris from Memorial Sloan Kettering, speaking again about the use of corticosteroids in oncology. Clearly, they’re one of our go-to agents, part of our standard antiemetic regimens, a cornerstone of the management of neurologic complications, and part of the management of many side effects, including dyspnea and anorexia. It’s very important to use corticosteroids… Read More »Finding the ‘Sweet Spot’ With Corticosteroids in Cancer Care.

  In medicine, lessons from rare genetic disorders can sometimes be turned into treatment for a common disease. Since the discovery that patients with sclerostin deficiency have surprisingly high bone mass,[1,2,3] inhibiting sclerostin has been an appealing strategy to treat osteoporosis. Romosozumab is a humanized monoclonal antibody against sclerostin, and its approval by the US Food and Drug Administration… Read More »Newly Approved Osteoporosis Drug Is ‘Promising’ and ‘Welcome’

The US Food and Drug Administration (FDA) has approved four generic versions of Gilead Sciences’ Letairis (ambrisentan), an endothelin receptor antagonist indicated for treatment for pulmonary arterial hypertension (PAH). The FDA first approved Letairis for PAH in 2007. Three generics are from Mylan Pharmaceuticals, Watson Laboratories, and Sun Pharma Global. The fourth generic is from Zydus Pharmaceuticals. In order to accommodate all four… Read More »FDA Approves Letairis (Ambrisentan) Generics for PAH.

  Long-duration androgen deprivation therapy (ADT) is widely underused in men, especially African Americans, who are undergoing definitive external beam radiotherapy (EBRT) for high-grade prostate cancer, a new U.S. study has found. Nearly a quarter of patients in the population-based retrospective trial received no long-term ADT, and fewer than one in seven received the recommended… Read More »Long-Term Androgen Deprivation Underused for Prostate Cancer.

  While there has been much progress made in recent years in the treatment of kidney cancer, all of it has been in the most common form of this disease, clear-cell renal cell carcinoma (ccRCC). Patients with the less common type of kidney cancer, non-clear-cell renal cell carcinoma (nccRCC), have usually been excluded from the large trials.… Read More »Cabozantinib Shows Promise in Non-Clear-Cell Kidney Cancer.

  Progress in both detection and management of breast cancer may have saved the lives of hundreds of thousands of women over the past three decades, according to a new report. The cumulative number of breast cancer deaths that have been averted since 1989 ranges between 384,000 and 614,500, depending on different background mortality assumptions.… Read More »Half A Million Breast Cancer Deaths Avoided In Last 30years.

  Treatment with the investigational agent darolutamide (Bayer/Orion) significantly extended metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), results from the phase 3 ARAMIS trial show. Darolutamide prolonged metastasis-free survival to 40.4 months, which was 22 months longer than observed with placebo, and the risk of metastasis or death from any cause was… Read More »Darolutamide : New Standard Of Care In Non Metastatic CRPC

This is Mark Kris from Memorial Sloan Kettering, speaking today about an emerging issue in our treatment of patients with lung cancers, and that is the use of immune checkpoint inhibitors in patients with a history of prior autoimmune disease. Many of us know that these patients were, by and large, excluded from clinical trials,… Read More »Checkpoint Inhibitor ‘Not Off Table’ For Patients With A History Of Autoimmune Disease.

Biliary tract cancers (BTCs) are rare, aggressive malignancies that generally have a poor prognosis, and are usually treated with chemotherapy. A new study shows that in a subgroup of these patients, individuals who have tumors with BRAF V600E mutations, treatment with a combination of targeted agents showed promising activity. The combination of drugs used — the BRAF kinase inhibitor… Read More »‘Impressive’ Activity with BRAF/MEK Inhibitors in Biliary Cancer